Oric Pharmaceuticals Stock Alpha and Beta Analysis
| ORIC Stock | USD 10.42 0.35 3.25% |
This module allows you to check different measures of market premium (i.e., alpha and beta) for all equities such as Oric Pharmaceuticals. It also helps investors analyze the systematic and unsystematic risks associated with investing in Oric Pharmaceuticals over a specified time horizon. Remember, high Oric Pharmaceuticals' alpha is almost always a sign of good performance; however, a high beta will depend on investors' risk tolerance level and may signal increased volatility and potential future overvaluation. Key technical indicators related to Oric Pharmaceuticals' market risk premium analysis include:
Beta 1.52 | Alpha 0.34 | Risk 5.03 | Sharpe Ratio 0.0559 | Expected Return 0.28 |
Enterprise Value |
|
Alpha is a measure of relative performance on a risk-adjusted basis, while beta measures volatility against the benchmark. The goal is to know if an investor is being compensated for the volatility risk taken. The return on investment might be better than its reference but still not compensate for the assumption of the risk.
Oric |
Oric Pharmaceuticals Market Premiums
Investors always prefer to have the highest possible return on investment, coupled with the lowest possible volatility. Oric Pharmaceuticals market risk premium is the additional return an investor will receive from holding Oric Pharmaceuticals long position in a well-diversified portfolio. The market premium is part of the Capital Asset Pricing Model (CAPM), which most analysts and investors use to calculate the acceptable rate of return on investment in Oric Pharmaceuticals. At the center of the CAPM is the concept of risk and reward, which is usually communicated by investors using alpha and beta measures. Alpha and beta are two of the key measurements used to evaluate Oric Pharmaceuticals' performance over market.| α | 0.34 | β | 1.52 |
Oric Pharmaceuticals expected buy-and-hold returns
Although buy-and-hold investment strategy may not appeal to all investors, it may be used as a good measure of Oric Pharmaceuticals' Buy-and-hold return. Our buy-and-hold chart shows how Oric Pharmaceuticals performed over your current time horizon against a typical interest-earning bank account and a selected benchmark.Oric Pharmaceuticals Market Price Analysis
Market price analysis indicators help investors to evaluate how Oric Pharmaceuticals stock reacts to ongoing and evolving market conditions. The investors can use it to make informed decisions about market timing, and determine when trading Oric Pharmaceuticals shares will generate the highest return on investment. By understating and applying Oric Pharmaceuticals stock market price indicators, traders can identify Oric Pharmaceuticals position entry and exit signals to maximize returns.
Oric Pharmaceuticals Return and Market Media
The median price of Oric Pharmaceuticals for the period between Sun, Nov 3, 2024 and Sat, Feb 1, 2025 is 9.41 with a coefficient of variation of 10.0. The daily time series for the period is distributed with a sample standard deviation of 0.93, arithmetic mean of 9.28, and mean deviation of 0.8. The Stock received a lot of media exposure during the period. Price Growth (%) |
| Timeline |
1 | We Think ORIC Pharmaceuticals Can Afford To Drive Business Growth | 12/12/2024 |
2 | Disposition of 16667 shares by Chacko Jacob of Oric Pharmaceuticals subject to Rule 16b-3 | 12/13/2024 |
3 | Disposition of 24660 shares by Chacko Jacob of Oric Pharmaceuticals at 8.2812 subject to Rule 16b-3 | 12/16/2024 |
4 | Oric Pharmaceuticals CEO Chacko Jacob sells 204,214 in stock - Investing.com | 12/17/2024 |
5 | Acquisition by Chacko Jacob of 300000 shares of Oric Pharmaceuticals at 4.36 subject to Rule 16b-3 | 12/27/2024 |
6 | Acquisition by Chacko Jacob of 100000 shares of Oric Pharmaceuticals subject to Rule 16b-3 | 01/02/2025 |
7 | ORIC Pharmaceuticals Reports Inducement Grantsunder Nasdaq Listing Rule 5635 | 01/03/2025 |
8 | ORIC Pharmaceuticals to Present at the 43rd AnnualJ.P. Morgan Healthcare Conference | 01/06/2025 |
9 | PriceSmart Posts Weak Earnings, Joins Roku And Other Big Stocks Moving Lower In Fridays Pre-Market Session | 01/10/2025 |
10 | ORIC Pharmaceuticals Provides Early Phase 1b Combination Data for ORIC-944, Operational Highlights for 2024, and Anticipated Upcoming Milestones | 01/13/2025 |
11 | HE Equipment Services, ACM Research, Robinhood And Other Big Stocks Moving Higher On Tuesday | 01/14/2025 |
12 | ORIC Pharmaceuticals Overweight Rating Reaffirmed at Cantor Fitzgerald | 01/17/2025 |
13 | Acquisition by Kunkel Lori Anne of 25600 shares of Oric Pharmaceuticals at 7.9 subject to Rule 16b-3 | 01/27/2025 |
About Oric Pharmaceuticals Beta and Alpha
For many years both, Alpha and Beta indicators are used by professional money managers as critical performance measurement tools across virtually all financial instruments including Oric or other stocks. Alpha measures the amount that position in Oric Pharmaceuticals has returned in comparison to a selected market index or another relevant benchmark. In other words, Alpha is the excess return on an investment relative to the performance of your selected benchmark. Beta, on the other hand, measures the relative risk of your investment.
| 2022 | 2023 | 2024 | 2025 (projected) | Current Ratio | 13.68 | 10.39 | 11.95 | 18.35 | Net Debt To EBITDA | 0.7 | 0.12 | 0.14 | 0.13 |
Oric Pharmaceuticals Upcoming Company Events
As portrayed in its financial statements, the presentation of Oric Pharmaceuticals' financial position is often influenced by management's estimates, judgments, and sometimes even manipulations. In the best case, Oric Pharmaceuticals' leadership is honest, while the outside auditors are strict and uncompromising. Whatever the case, investors should always follow all of Oric Pharmaceuticals' public filing events to personally review all filings and be reasonable and skeptical to interpret all of the financial statements of Oric Pharmaceuticals. Please utilize our Beneish M Score to check the likelihood of Oric Pharmaceuticals' management manipulating its earnings.
| 21st of March 2024 Upcoming Quarterly Report | View | |
| 13th of May 2024 Next Financial Report | View | |
| 31st of December 2023 Next Fiscal Quarter End | View | |
| 21st of March 2024 Next Fiscal Year End | View | |
| 30th of September 2023 Last Quarter Report | View | |
| 31st of December 2022 Last Financial Announcement | View |
Build Portfolio with Oric Pharmaceuticals
Your optimized portfolios are the building block of your wealth. We provide an intuitive interface to determine which securities in a portfolio should be removed or rebalanced to achieve better diversification, find the right mix of securities that minimizes portfolio risk for a given return, or maximize portfolio expected return for a given risk level.Build Diversified Portfolios
Align your risk with return expectations
Check out Oric Pharmaceuticals Backtesting, Oric Pharmaceuticals Valuation, Oric Pharmaceuticals Correlation, Oric Pharmaceuticals Hype Analysis, Oric Pharmaceuticals Volatility, Oric Pharmaceuticals History and analyze Oric Pharmaceuticals Performance. For information on how to trade Oric Stock refer to our How to Trade Oric Stock guide.You can also try the Crypto Correlations module to use cryptocurrency correlation module to diversify your cryptocurrency portfolio across multiple coins.
Oric Pharmaceuticals technical stock analysis exercises models and trading practices based on price and volume transformations, such as the moving averages, relative strength index, regressions, price and return correlations, business cycles, stock market cycles, or different charting patterns.